Abstract
Get full access to this article
View all access options for this article.
References
1.
Filice
GA
McDougall
BC
Ercan-Fang
N
Billington
CJ
. Neuroleptic malignant syndrome associated with olanzapine . Ann Pharmacother
1998 ;32 :1158 –9 .
2.Adityanjee.
The myth of elevated serum creatine phosphokinase and neuroleptic malignant syndrome . Br J Psychiatry
1991 ;158 :706 –7 .
3.
O'Dwyer
AM
Sheppard
NP
. The role of creatine kinase in the diagnosis of neuroleptic malignant syndrome . Psychol Med
1993 ;23 :323 –6 .
4.
Naranjo
CA
Busto
U
Sellers
EM
Sandor
P
Ruiz
I
Roberts
EA
A method for estimating the probability of adverse drug reactions . Clin Pharmacol Ther
1981 ;30 :239 –45 .
5.
Martin
TG
. Serotonin syndrome . Ann Emerg Med
1996 ;28 :520 –6 .
6.
Chan
BS
Graudins
A
Whyte
IM
Dawson
AH
Braitberg
G
Duggin
GG
. Serotonin syndrome resulting from drug interactions . Med J Aust
1998 ;169 :523 –5 .